Literature DB >> 15274204

Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator.

Edwin A Burgstaler1, Alvaro A Pineda, Jeffrey L Winters.   

Abstract

A technique for large volume leukapheresis (LVL) for hematopoietic progenitor cell (HPC) collection using the Fenwal Amicus is presented. It was compared to standard collections (STD) with regard to CD34+ cell yields and cross-cellular content. Optimal cycle volumes and machine settings were evaluated for LVL procedures. A total of 68 patients underwent 80 HPC collection procedures. Because of differences in CD34+ cell yields associated with peripheral white blood cell counts (WBC), the comparison was divided into groups of 20 with WBC < or =35 x 10(9)/L (< or =35 K) and those >35 x 10(9)/L (>35 K). Baseline CD34+ cell counts (peripheral count when patient started HPC collection) were used (median 18-23 cells/microl). Significantly more whole blood (corrected for anticoagulant) was processed with LVL (LVL 20 l vs. STD 13.5 l). For < or =35 K, median CD34+ x 10(6), WBC x 10(9), RBC ml, Plt x 10(11) yields/collection were 183, 21.2, 14, 0.8, respectively, for STD vs. 307, 22.1, 11, 1.0, respectively, for LVL. For >35 K, median CD34+ x 10(6), WBC x 10(9), RBC ml, Plt x 10(11) yields/collection were 189, 32.7, 15, 1.4, respectively, for STD vs. 69, 40.8, 21, 1.3, respectively, for LVL. We have described a method of LVL using the Amicus that, in patients with pre-procedure WBC < or =35 x 10(9)/L, collects more CD34+ cells than a standard procedure with acceptable cross-cellular content. This method is not recommended when pre-procedure WBC counts are >35 x 10(9)/L.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15274204     DOI: 10.1002/jca.20011

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  2 in total

1.  Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.

Authors:  M A Gertz; S K Kumar; M Q Lacy; A Dispenzieri; S R Hayman; F K Buadi; D Dingli; D A Gastineau; J L Winters; M R Litzow
Journal:  Bone Marrow Transplant       Date:  2008-11-10       Impact factor: 5.483

2.  Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.

Authors:  S K Kumar; J Mikhael; B Laplant; M Q Lacy; F K Buadi; D Dingli; M A Gertz; K Laumann; T Miceli; M Mahlman; L P Bergsagel; S R Hayman; C Reeder; A K Stewart; A Dispenzieri; D A Gastineau; J L Winters
Journal:  Bone Marrow Transplant       Date:  2013-11-04       Impact factor: 5.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.